

Intellectual Property and Access to Medicines in Europe

Revisiting the Incentives Framework

Wednesday, 16 May, 2018
9.30–11.30
European Parliament, Brussels
Room A3H-1

[Register](#)

Health Action International invites you to a roundtable discussion, with key stakeholders from European Union (EU) institutions and civil society, to share perspectives on the intellectual property (IP) incentives framework and access to medicines in Europe.

BACKGROUND

High-priced medicines, resulting from the current IP incentives framework, have become an increasingly relevant problem, not only in low- and middle-income countries, but also in high-income ones. As such, there is renewed scrutiny of the impact of IP rights and incentives, and numerous calls to make use of the flexibilities in the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement—and other IP management tools—in containing costs and improving and securing access to medicines in the EU and beyond.

PROGRAMME

Hosted by Nessa Childers MEP (S&D, ENVI) and José Inácio Faria MEP (EPP, ENVI)

Opening Remarks: Jaume Vidal, Policy Advisor, Health Action International

Roundtable Discussion: Intellectual Property and Access to Medicines in Europe: Revisiting the Incentives Framework

Moderator: Agustín Reyna, Chief Competition Advisor, The European Consumer Organisation (BEUC)

Interventions:

- Nessa Childers MEP
- José Inácio Faria MEP
- Denis Dambois, Industrial Property and the Fight Against Counterfeiting, European Commission (DG GROW)
- Dr Ellen 't Hoen, IP Rights Expert, Global Health Unit, University Medical Center Groningen; Director, Medicines Law and Policy
- HU Yuan Qiong, Senior Legal and Policy Advisor, Médecins Sans Frontières Access Campaign
- Adrian van den Hoven, Director General, Medicines for Europe

Open Discussion and Conclusions

[Register](#)